09/02/2026
340B growth is often discussed in simple terms — but the data tells a more complex story.
In this episode of Katy’s 340B Compass, Katy Lees looks at why rising 340B spending should not be separated from rising drug acquisition costs, increasing patient complexity, and broader changes in healthcare delivery.
You’ll hear why price, total spending, utilization, and patient acuity are different measures — and why that distinction matters for honest policy discussions, stronger oversight, and better organizational decision-making.
Visit Virtue 340B’s website to watch or listen to the episode on your preferred platform.
https://virtue340b.com/content-hub/katys-340b-compass/
Watch Katy Lees, 340B ACE-certified advisor, break down complex compliance topics with practical guidance you can apply to your program today.